Cohen A, et al. - For the treatment of relapsed/refractory multiple myeloma (MM) patients, researchers evaluated the combination of pomalidomide (POM) with dexamethasone (DEX) 40 mg and pegylated liposomal doxorubicin (PLD) 5 mg/m² with the latter two drugs administered on days 1, 4, 8 and 11 on a 28-day cycle. As per findings, POM, PLD and DEX seemed a treatment option for relapsed/refractory MM patients including those who were refractory to lenalidomide.